BioCentury | Feb 21, 2019
Distillery Therapeutics

Cancer

...a humanized IgG1 anti-BCMA antibody and monomethyl auristatin F, in Phase II to treat MM. Heidelberg Pharma AG...
BioCentury | Sep 26, 2018
Distillery Therapeutics

Cancer

...to the liver. Next steps could include optimizing and testing the compounds in the models. Heidelberg Pharma AG...
BioCentury | Nov 10, 2017
Financial News

Telix raises A$50M in Australian IPO

...as Wilex AG (see BioCentury, Jan. 20 ). Telix Pharmaceuticals Ltd. (ASX:TLX), North Melbourne, Australia Jennie Walters girentuximab Heidelberg Pharma AG Telix...
...AG (see BioCentury, Jan. 20 ). Telix Pharmaceuticals Ltd. (ASX:TLX), North Melbourne, Australia Jennie Walters girentuximab Heidelberg Pharma AG Telix Pharmaceuticals Ltd. Wilex...
BioCentury | Nov 9, 2017
Financial News

Telix raises A$50M in Australian IPO

...January, Telix gained exclusive rights to girentuximab from Heidelberg Pharma AG (Xetra:WL6), formerly known as Wilex AG. Jennie Walters girentuximab Heidelberg Pharma AG Telix...
BioCentury | Feb 10, 2017
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

...Wilex's Heidelberg Pharma GmbH subsidiary exercised an option under a 2016 deal to license humanized antibodies against...
...HDP-101 as the lead compound and said it expects to begin clinical trials in 2018. Wilex...
...Berlin, Germany Wilex AG (Xetra:WL6), Munich, Germany Business: Cancer Alicia Parker HDP-101 Max Delbrueck Center for Molecular Medicine Berlin-Buch Wilex...
BioCentury | Jan 20, 2017
Company News

Wilex, Telix deal

...clear cell renal cell carcinoma (RCC). Telix is responsible for all development and commercialization costs. Wilex...
...and will evaluate the use of carbonic anhydrase IX (CAIX)-targeting therapeutic agents for cancer-related malignancies. Wilex...
...additional financial terms. Wilex AG (Xetra:WL6), Munich, Germany Telix Pharmaceuticals Ltd., Melbourne, Australia Business: Cancer Shannon Lehnbeuter 124-Iodine-girentuximab Redectane WX-G250 Wilex...
BioCentury | Oct 31, 2016
Company News

Nordic Nanovector, Wilex deal

...Nordic Nanovector and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to develop antibody-drug conjugates (ADCs) to treat leukemia...
...ADCs) to treat leukemia. Nordic Nanovector will provide an undisclosed antibody against leukemia cells, and Heidelberg Pharma...
...lymphoma (NHL). The companies declined to disclose financial terms. Nordic Nanovector ASA (OSE:NANO), Oslo, Norway Wilex...
BioCentury | Oct 17, 2016
Financial News

Financial News

Wilex AG WIR Staff...
BioCentury | Sep 26, 2016
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

...The Max Delbrueck Center ( MDC ) granted Wilex’s Heidelberg Pharma GmbH subsidiary an option to license...
...antibody targeted amanitin conjugates (ATAC) technology to start in 2018 to treat multiple myeloma (MM). Wilex...
...did not respond to inquiries. Max Delbrueck Center for Molecular Medicine Berlin-Buch , Berlin, Germany Wilex...
BioCentury | Jun 27, 2016
Company News

Advanced Proteome Therapeutics, Wilex deal

...Advanced Proteome and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to create antibody-drug conjugates (ADCs) to treat cancer...
...the deal and declined to disclose financial terms. Advanced Proteome Therapeutics Corp. (TSX-V:APC;FSE:0E8), Boston, Mass. Wilex...
Items per page:
1 - 10 of 307
BioCentury | Feb 21, 2019
Distillery Therapeutics

Cancer

...a humanized IgG1 anti-BCMA antibody and monomethyl auristatin F, in Phase II to treat MM. Heidelberg Pharma AG...
BioCentury | Sep 26, 2018
Distillery Therapeutics

Cancer

...to the liver. Next steps could include optimizing and testing the compounds in the models. Heidelberg Pharma AG...
BioCentury | Nov 10, 2017
Financial News

Telix raises A$50M in Australian IPO

...as Wilex AG (see BioCentury, Jan. 20 ). Telix Pharmaceuticals Ltd. (ASX:TLX), North Melbourne, Australia Jennie Walters girentuximab Heidelberg Pharma AG Telix...
...AG (see BioCentury, Jan. 20 ). Telix Pharmaceuticals Ltd. (ASX:TLX), North Melbourne, Australia Jennie Walters girentuximab Heidelberg Pharma AG Telix Pharmaceuticals Ltd. Wilex...
BioCentury | Nov 9, 2017
Financial News

Telix raises A$50M in Australian IPO

...January, Telix gained exclusive rights to girentuximab from Heidelberg Pharma AG (Xetra:WL6), formerly known as Wilex AG. Jennie Walters girentuximab Heidelberg Pharma AG Telix...
BioCentury | Feb 10, 2017
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

...Wilex's Heidelberg Pharma GmbH subsidiary exercised an option under a 2016 deal to license humanized antibodies against...
...HDP-101 as the lead compound and said it expects to begin clinical trials in 2018. Wilex...
...Berlin, Germany Wilex AG (Xetra:WL6), Munich, Germany Business: Cancer Alicia Parker HDP-101 Max Delbrueck Center for Molecular Medicine Berlin-Buch Wilex...
BioCentury | Jan 20, 2017
Company News

Wilex, Telix deal

...clear cell renal cell carcinoma (RCC). Telix is responsible for all development and commercialization costs. Wilex...
...and will evaluate the use of carbonic anhydrase IX (CAIX)-targeting therapeutic agents for cancer-related malignancies. Wilex...
...additional financial terms. Wilex AG (Xetra:WL6), Munich, Germany Telix Pharmaceuticals Ltd., Melbourne, Australia Business: Cancer Shannon Lehnbeuter 124-Iodine-girentuximab Redectane WX-G250 Wilex...
BioCentury | Oct 31, 2016
Company News

Nordic Nanovector, Wilex deal

...Nordic Nanovector and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to develop antibody-drug conjugates (ADCs) to treat leukemia...
...ADCs) to treat leukemia. Nordic Nanovector will provide an undisclosed antibody against leukemia cells, and Heidelberg Pharma...
...lymphoma (NHL). The companies declined to disclose financial terms. Nordic Nanovector ASA (OSE:NANO), Oslo, Norway Wilex...
BioCentury | Oct 17, 2016
Financial News

Financial News

Wilex AG WIR Staff...
BioCentury | Sep 26, 2016
Company News

Max Delbrueck Center for Molecular Medicine Berlin-Buch, Wilex deal

...The Max Delbrueck Center ( MDC ) granted Wilex’s Heidelberg Pharma GmbH subsidiary an option to license...
...antibody targeted amanitin conjugates (ATAC) technology to start in 2018 to treat multiple myeloma (MM). Wilex...
...did not respond to inquiries. Max Delbrueck Center for Molecular Medicine Berlin-Buch , Berlin, Germany Wilex...
BioCentury | Jun 27, 2016
Company News

Advanced Proteome Therapeutics, Wilex deal

...Advanced Proteome and Wilex’s Heidelberg Pharma GmbH subsidiary partnered to create antibody-drug conjugates (ADCs) to treat cancer...
...the deal and declined to disclose financial terms. Advanced Proteome Therapeutics Corp. (TSX-V:APC;FSE:0E8), Boston, Mass. Wilex...
Items per page:
1 - 10 of 307